BACKGROUND: Roux-en-Y gastric bypass (RYGBP) is a validated technique for the treatment of morbid obesity and results in a significant rate of remission of type 2 diabetes (T2D). Omega gastric bypass (OGBP) is an effective and simpler alternative for weight loss, but its effect on T2D is unclear. METHODS: Between December 2006 and September 2012, 804 laparoscopic OGBPs were carried out in our centre. Among these, 100 (12.4%) patients had T2D at the time of the intervention. Remission of T2D was defined by a glycated haemoglobin (HbA1c) level of <6% without concomitant treatment. RESULTS: Postoperative follow-up was completed by 81 patients (mean age: 49 ± 11 years; mean weight at surgery: 133 ± 29 kg; mean body mass index (BMI): 47 ± 9 kg/m(2)). Mean preoperative HbA1c was 8 ± 2 g/dL. Before OGBP, seven patients (9%) had received no oral hypoglycaemic treatment, 30 (37%) had received monotherapy, 26 (32%) bitherapy, six (7%) tritherapy and 12 (15%) patients had used insulin. Over a mean follow-up of 26 months (range 1-75), mean weight decreased to 94 ± 23 kg and mean BMI to 35 kg/m(2). Seventy-one (88%) patients had complete remission of T2D and the other 10 (12%) had reduced their treatment. Seven patients (58%) initially treated with insulin no longer required this treatment. Mean time to remission of T2D for patients receiving one or more oral therapies versus insulin was 6.9 versus 17.9 months. CONCLUSIONS: OMBP is effective treatment for obesity in terms of weight loss and remission of T2D.
BACKGROUND: Roux-en-Y gastric bypass (RYGBP) is a validated technique for the treatment of morbid obesity and results in a significant rate of remission of type 2 diabetes (T2D). Omega gastric bypass (OGBP) is an effective and simpler alternative for weight loss, but its effect on T2D is unclear. METHODS: Between December 2006 and September 2012, 804 laparoscopic OGBPs were carried out in our centre. Among these, 100 (12.4%) patients had T2D at the time of the intervention. Remission of T2D was defined by a glycated haemoglobin (HbA1c) level of <6% without concomitant treatment. RESULTS: Postoperative follow-up was completed by 81 patients (mean age: 49 ± 11 years; mean weight at surgery: 133 ± 29 kg; mean body mass index (BMI): 47 ± 9 kg/m(2)). Mean preoperative HbA1c was 8 ± 2 g/dL. Before OGBP, seven patients (9%) had received no oral hypoglycaemic treatment, 30 (37%) had received monotherapy, 26 (32%) bitherapy, six (7%) tritherapy and 12 (15%) patients had used insulin. Over a mean follow-up of 26 months (range 1-75), mean weight decreased to 94 ± 23 kg and mean BMI to 35 kg/m(2). Seventy-one (88%) patients had complete remission of T2D and the other 10 (12%) had reduced their treatment. Seven patients (58%) initially treated with insulin no longer required this treatment. Mean time to remission of T2D for patients receiving one or more oral therapies versus insulin was 6.9 versus 17.9 months. CONCLUSIONS: OMBP is effective treatment for obesity in terms of weight loss and remission of T2D.
Authors: Miguel Carbajo; Manuel García-Caballero; Miguel Toledano; Diego Osorio; Cándido García-Lanza; José Antonio Carmona Journal: Obes Surg Date: 2005-03 Impact factor: 4.129
Authors: David E Arterburn; Andy Bogart; Nancy E Sherwood; Stephen Sidney; Karen J Coleman; Sebastien Haneuse; Patrick J O'Connor; Mary Kay Theis; Guilherme M Campos; David McCulloch; Joe Selby Journal: Obes Surg Date: 2013-01 Impact factor: 4.129
Authors: John P Bantle; Judith Wylie-Rosett; Ann L Albright; Caroline M Apovian; Nathaniel G Clark; Marion J Franz; Byron J Hoogwerf; Alice H Lichtenstein; Elizabeth Mayer-Davis; Arshag D Mooradian; Madelyn L Wheeler Journal: Diabetes Care Date: 2008-01 Impact factor: 19.112
Authors: Guilherme M Campos; Charlotte Rabl; Kathleen Mulligan; Andrew Posselt; Stanley J Rogers; Antonio C Westphalen; Feng Lin; Eric Vittinghoff Journal: Arch Surg Date: 2008-09
Authors: Maurizio De Luca; Giacomo Piatto; Giovanni Merola; Jacques Himpens; Jean-Marc Chevallier; Miguel-A Carbajo; Kamal Mahawar; Alberto Sartori; Nicola Clemente; Miguel Herrera; Kelvin Higa; Wendy A Brown; Scott Shikora Journal: Obes Surg Date: 2021-05-03 Impact factor: 4.129
Authors: Maurizio De Luca; Tiffany Tie; Geraldine Ooi; Kelvin Higa; Jacques Himpens; Miguel-A Carbajo; Kamal Mahawar; Scott Shikora; Wendy A Brown Journal: Obes Surg Date: 2018-05 Impact factor: 4.129
Authors: Mario Musella; Jan Apers; Karl Rheinwalt; Rui Ribeiro; Emilio Manno; Francesco Greco; Michal Čierny; Marco Milone; Carla Di Stefano; Sahin Guler; Isa Mareike Van Lessen; Anabela Guerra; Mauro Natale Maglio; Riccardo Bonfanti; Radoslava Novotna; Guido Coretti; Luigi Piazza Journal: Obes Surg Date: 2016-05 Impact factor: 4.129
Authors: Miguel A Carbajo; Enrique Luque-de-León; José M Jiménez; Javier Ortiz-de-Solórzano; Manuel Pérez-Miranda; María J Castro-Alija Journal: Obes Surg Date: 2017-05 Impact factor: 4.129